ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Shareholders Beware

<< Previous

Bullboard Posts

Next >>

Comment by BottomBrokeron Nov 02, 2021 3:47pm

106 Views

Post# 34078928

RE:RE:Shareholders Beware

TopBroker/goldtech has also said he's an elite financial Wall St.-type. He has said that he doesn't own any shares, and that he was simply asked by a friend to give an analysis of PMN. This was many months ago, and yet, he's still here.

Don't put a lot of 'stock' into anything TopBroker/goldtech says.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks